Anti-cytokine Therapy in Fibrosing Alveolitis: Where Are We Now?

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2001 Oct 23

PMID 11667955

Citations 1

Authors

A Millar

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median survival of 4-5 years irrespective of treatment. Ziesche et al (N Engl J Med 1999, 341: 1264-1269) describe an open randomised trial of 18 patients with IPF, unresponsive to corticosteroid treatment at high dose. Nine patients were treated with continued corticosteroid and nine with prednisolone plus interferon-gamma 1b (IFN-gamma). Significant benefits in physiological parameters are reported in the IFN-gamma-treated group. An analysis of lung tissue by reverse-transcriptase-mediated polymerase chain reaction showed corresponding decreases in the transcription of transforming growth factor-beta1 and connective tissue growth factor. This is the first report of treatment showing efficacy in this disease, albeit in a very preliminary study, but the data should be viewed with caution. This study is discussed in the context of other published studies of treatment for IPF and the scientific rationale on which it was based.

Citing Articles

IL-10: Another therapeutic target in idiopathic pulmonary fibrosis?.

Millar A Thorax. 2006; 61(10):835-6.

PMID: 17008481 PMC: 2104749. DOI: 10.1136/thx.2006.060772.

References

. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1):646-64. DOI: 10.1164/ajrccm.161.2.ats3-00. View

Ziesche R, Hofbauer E, Wittmann K, Petkov V, BLOCK L . A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999; 341(17):1264-9. DOI: 10.1056/NEJM199910213411703. View

WINTERBAUER R, Hammar S, Hallman K, Hays J, Pardee N, Morgan E . Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med. 1978; 65(4):661-72. DOI: 10.1016/0002-9343(78)90855-0. View

TURNER-WARWICK M, Burrows B, Johnson A . Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax. 1980; 35(3):171-80. PMC: 471249. DOI: 10.1136/thx.35.3.171. View

TURNER-WARWICK M, Burrows B, Johnson A . Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax. 1980; 35(8):593-9. PMC: 471341. DOI: 10.1136/thx.35.8.593. View

Rudd R, Haslam P, TURNER-WARWICK M . Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis. 1981; 124(1):1-8. DOI: 10.1164/arrd.1981.124.1.1. View

Johnson M, Kwan S, Snell N, Nunn A, Darbyshire J, TURNER-WARWICK M . Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax. 1989; 44(4):280-8. PMC: 461792. DOI: 10.1136/thx.44.4.280. View

Panos R, Mortenson R, Niccoli S, King Jr T . Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990; 88(4):396-404. DOI: 10.1016/0002-9343(90)90495-y. View

Raghu G, DePaso W, Cain K, Hammar S, Wetzel C, Dreis D . Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991; 144(2):291-6. DOI: 10.1164/ajrccm/144.2.291. View

10.

Broekelmann T, Limper A, Colby T, McDonald J . Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A. 1991; 88(15):6642-6. PMC: 52144. DOI: 10.1073/pnas.88.15.6642. View

11.

Baughman R, Lower E . Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest. 1992; 102(4):1090-4. DOI: 10.1378/chest.102.4.1090. View

12.

Dayton C, Schwartz D, Helmers R, Pueringer R, Gilbert S, MERCHANT R . Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest. 1993; 103(1):69-73. DOI: 10.1378/chest.103.1.69. View

13.

Schwartz D, Helmers R, Galvin J, Van Fossen D, Frees K, Dayton C . Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994; 149(2 Pt 1):450-4. DOI: 10.1164/ajrccm.149.2.8306044. View

14.

Kasama T, Strieter R, Lukacs N, Lincoln P, Burdick M, Kunkel S . Interferon gamma modulates the expression of neutrophil-derived chemokines. J Investig Med. 1995; 43(1):58-67. View

15.

Mapel D, Samet J, Coultas D . Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest. 1996; 110(4):1058-67. DOI: 10.1378/chest.110.4.1058. View

16.

Baumgartner K, Samet J, Stidley C, Colby T, Waldron J . Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997; 155(1):242-8. DOI: 10.1164/ajrccm.155.1.9001319. View

17.

Bjoraker J, Ryu J, Edwin M, Myers J, Tazelaar H, Schroeder D . Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 157(1):199-203. DOI: 10.1164/ajrccm.157.1.9704130. View

18.

Grotendorst G . Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1998; 8(3):171-9. DOI: 10.1016/s1359-6101(97)00010-5. View

19.

Katzenstein A, Myers J . Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998; 157(4 Pt 1):1301-15. DOI: 10.1164/ajrccm.157.4.9707039. View

20.

DOUGLAS W, Ryu J, Swensen S, Offord K, Schroeder D, Caron G . Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med. 1998; 158(1):220-5. DOI: 10.1164/ajrccm.158.1.9709089. View